Chromogranin A (CGA)-derived polypeptide (CGA47-66) inhibits TNF-α-induced vascular endothelial hyper-permeability through SOC-related Ca2+ signaling

Peptides. 2020 Sep:131:170297. doi: 10.1016/j.peptides.2020.170297. Epub 2020 May 5.

Abstract

CGA1-78 (Vasostatin-1, VS-1) a N-terminal Chromogranin A (CGA)-derived peptide, has been shown to have a protective effect against TNF-α-induced impairment of endothelial cell integrity. However, the mechanisms of this effect have not yet been clarified. CGA47-66 (Chromofungin, CHR) is an important bioactive fragment of CGA1-78. The present study aims to explore the protective effects of CHR on the vascular endothelial cell barrier response to TNF-α and its related Ca2+ signaling mechanisms. EA.hy926 cells were used as a vascular endothelial culture model. The synthetic peptides CHR and CGA4-16 were assessed for their ability to suppress TNF-α-induced EA.hy926 cells hyper-permeability through Transwell® and TEER assays. Changes in [Ca2+]i were measured through confocal laser scanning microscopy. SOC channel currents (Isoc) were measured via patch-clamp analysis. RT-PCR and western blot were used to analyze mRNA and protein expression of the transient receptor potential channels TRPC1 and TRPC4, respectively. FITC and rhodamine-phalloidin fluorescence were used to assess cell morphology and the distribution of MyPT-1 and F-actin. Compared to untreated cells, TNF-α increased the permeability of EA.hy926 cells that was inhibited by pre-treatment with CHR (10-1000 nM) in concentration-dependent manner, and the effect was most obvious at 100 nM, but CGA4-16 (100 nM) had no effect. TNF-α treatment increased the phosphorylation of MyPT-1 and stress fiber formation. CHR (10-1000 nM) pretreatment inhibited the cytoskeletal rearrangements and increased [Ca2+]i in response to TNF-α treatment. CHR also reduced TRPC1 expression following TNF-α induction. Similar to SOC inhibitor 2-APB, CHR suppressed IP3 mediated SOC activation. These findings suggest that CHR inhibits TNF-α-induced Ca2+ influx and protects the barrier function of vascular endothelial cells, and that these effects are related to the inhibition of SOC and Ca2+ signaling by CHR.

Keywords: Ca(2+); Chromofungin; Chromogranin A; SOC; TNF-α; Vascular endothelial cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Actin Cytoskeleton / drug effects
  • Actin Cytoskeleton / metabolism
  • Actin Cytoskeleton / ultrastructure
  • Actins / genetics
  • Actins / metabolism
  • Calcium / metabolism
  • Calcium Signaling / drug effects*
  • Cell Line, Transformed
  • Cell Membrane Permeability / drug effects
  • Chromogranin A / pharmacology*
  • Diffusion Chambers, Culture
  • Dose-Response Relationship, Drug
  • Endothelial Cells / cytology
  • Endothelial Cells / drug effects*
  • Endothelial Cells / metabolism
  • Gene Expression Regulation
  • Humans
  • Inositol 1,4,5-Trisphosphate / metabolism
  • Myosin-Light-Chain Phosphatase / genetics
  • Myosin-Light-Chain Phosphatase / metabolism
  • Patch-Clamp Techniques
  • Peptide Fragments / pharmacology*
  • Phosphorylation
  • TRPC Cation Channels / antagonists & inhibitors
  • TRPC Cation Channels / genetics
  • TRPC Cation Channels / metabolism*
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • Actins
  • Chromogranin A
  • Peptide Fragments
  • TRPC Cation Channels
  • TRPC4 ion channel
  • Tumor Necrosis Factor-alpha
  • chromofungin
  • transient receptor potential cation channel, subfamily C, member 1
  • vasostatin I
  • Inositol 1,4,5-Trisphosphate
  • Myosin-Light-Chain Phosphatase
  • PPP1R12A protein, human
  • Calcium